Brief: Cyclo Therapeutics Achieves Landmark Milestone With Completion Of Enrollment Of Last Patient In Phase 3 Pivotal Transportnpc™ Trial Of Niemann-Pick Type C1
30/05/2024 14:07
May 30 (Reuters) - Cyclo Therapeutics Inc CYTH.O :
* CYCLO THERAPEUTICS ACHIEVES LANDMARK MILESTONE WITH
COMPLETION
OF ENROLLMENT OF LAST PATIENT IN PHASE 3 PIVOTAL TRANSPORTNPC™
TRIAL OF NIEMANN-PICK TYPE C1
* CYCLO THERAPEUTICS : TOPLINE DATA FROM 48-WEEK INTERIM
ANALYSIS
OF 104 ENROLLED PATIENTS IS ANTICIPATED FOR H1 2025
* CYCLO THERAPEUTICS : SUBMISSION OF NDA TO FDA & MARKETING
AUTHORIZATION APPLICATION TO EUROPEAN MEDICINES AGENCY IS
TARGETED FOR 2H 2025
Source text for Eikon: ID:nBw8WcpX8a
Further company coverage: CYTH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rafael Holdings
See all newsBrief: Rafael Holdings Announces Topline Results From The Pivotal Phase 3 Transportnpc™ Study Of Trappsol® Cyclo™ In Niemann-Pick Disease Type C (Npc)
Israel expects new air defence orders from Europe due to Russia concerns
Biotech firm Rafael's Q3 net loss narrows; set to submit NDA for Trappsol Cyclo in H2
Rafael Holdings Q2 net loss widens on consolidation of Cyclo Therapeutic's costs
Brief: Rafael Holdings Q2 Net Income USD -6.327 Million